Nymox Pharmaceutical Corporation (NYMXF)

Nymox Pharmaceutical Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 24, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Market Capitalization	10	55	30	110	192	154
Market Cap Growth	86.49%	86.49%	-73.23%	-42.54%	24.63%	84.41%
Enterprise Value	11	55	27	108	187	147
Last Close Price	0.11	0.59	0.32	1.30	2.48	2.20
PE Ratio	-	-6.12	-4.39	-8.50	-15.60	-11.51
PS Ratio	-	-	-	-	38367.59	1326.99
PB Ratio	-17.34	-17.34	-61.22	-217.86	89.43	44.64
P/FCF Ratio	-13.55	-13.55	-5.67	-11.22	-19.09	-20.72
P/OCF Ratio	-13.56	-13.56	-5.67	-11.23	-19.11	-20.72
EV/Sales Ratio	-	-	-	-	37312.99	1267.28
EV/EBITDA Ratio	-6.59	-6.59	-4.07	-8.61	-15.93	-11.04
EV/EBIT Ratio	-6.58	-6.58	-4.06	-8.60	-15.92	-11.03
EV/FCF Ratio	-2.70	-13.54	-5.19	-10.94	-18.56	-19.79
Debt / Equity Ratio	-0.24	-0.24	-0.36	-0.77	0.20	0.04
Debt / FCF Ratio	-0.18	-0.18	-0.03	-0.04	-0.04	-0.02
Asset Turnover	-	-	-	-	0.00	0.02
Inventory Turnover	-	-	-	-	0.14	1.81
Quick Ratio	0.02	0.02	0.67	0.47	1.85	2.58
Current Ratio	0.16	0.16	0.69	0.58	1.98	2.61
Return on Equity (ROE)	-	-	-	-1529.84%	-419.74%	-251.90%
Return on Assets (ROA)	-463.48%	-463.48%	-271.02%	-270.13%	-149.00%	-122.79%
Return on Capital (ROIC)	-	-	-	-636.40%	-237.59%	-157.18%
Earnings Yield	-87.69%	-16.07%	-22.29%	-11.37%	-6.12%	-8.55%
FCF Yield	-39.46%	-7.38%	-17.64%	-8.91%	-5.24%	-4.83%
Buyback Yield / Dilution	-2.58%	-2.58%	-9.03%	-11.04%	-7.23%	-13.86%
Total Shareholder Return	-2.58%	-2.58%	-9.03%	-11.04%	-7.23%	-13.86%

Source: S&P Capital IQ. Standard template. Financial Sources.